.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Cantor Fitzgerald
Harvard Business School
Novartis
Johnson and Johnson
QuintilesIMS
Cipla
Accenture
Fish and Richardson
Teva

Generated: November 25, 2017

DrugPatentWatch Database Preview

Desonide - Generic Drug Details

« Back to Dashboard

What are the generic sources for desonide and what is the scope of desonide patent protection?

Desonide
is the generic ingredient in four branded drugs marketed by Perrigo New York, Galderma Labs Lp, G And W Labs Inc, Glenmark Pharms, Hi-tech Pharmacal, Bayer Hlthcare, Taro, Fougera Pharms, Teligent Pharma Inc, Taro Pharm, Aqua Pharms, and Glenmark Pharms Ltd, and is included in eighteen NDAs. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Desonide has eighty-two patent family members in twenty-five countries and ten supplementary protection certificates in nine countries.

There are twenty-nine drug master file entries for desonide. Seventeen suppliers are listed for this compound.

Pharmacology for desonide

Medical Subject Heading (MeSH) Categories for desonide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teligent Pharma Inc
DESONIDE
desonide
LOTION;TOPICAL207855-001Sep 28, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro
DESONIDE
desonide
OINTMENT;TOPICAL074254-001Aug 3, 1994ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm
DESONIDE
desonide
LOTION;TOPICAL202161-001Oct 31, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Aqua Pharms
VERDESO
desonide
AEROSOL, FOAM;TOPICAL021978-001Sep 19, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Perrigo New York
DESONIDE
desonide
CREAM;TOPICAL017010-001Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Galderma Labs Lp
DESOWEN
desonide
LOTION;TOPICAL072354-001Jan 24, 1992ABRXNoYes► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
DESONATE
desonide
GEL;TOPICAL021844-001Oct 20, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
Aqua Pharms
VERDESO
desonide
AEROSOL, FOAM;TOPICAL021978-001Sep 19, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Glenmark Pharms
DESONIDE
desonide
LOTION;TOPICAL209494-001Sep 26, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro
DESONIDE
desonide
CREAM;TOPICAL073548-001Jun 30, 1992ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: desonide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,517,847 Topical gel delivery system► Subscribe
8,263,580Vitamin formulation► Subscribe
8,629,128Vitamin formulation► Subscribe
8,298,515Vitamin formulation► Subscribe
8,449,867Microemulsion and sub-micron emulsion process and compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: desonide

Country Document Number Estimated Expiration
BrazilPI0514806► Subscribe
Japan4972553► Subscribe
Canada2578594► Subscribe
Japan2002524490► Subscribe
Poland360589► Subscribe
Cyprus1114646► Subscribe
Portugal1112062► Subscribe
Spain2437321► Subscribe
South Africa200301037► Subscribe
Cyprus1109189► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: DESONIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/033United Kingdom► SubscribePRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
2013025,C1304992Lithuania► SubscribePRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
13/044Ireland► SubscribePRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
401Luxembourg► SubscribePRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
4Finland► Subscribe
2013025Lithuania► SubscribePRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
1304992/01Switzerland► SubscribePRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
90049-3Sweden► SubscribePRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
2013 00053Denmark► SubscribePRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
00617Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Chinese Patent Office
Dow
Farmers Insurance
Cerilliant
US Department of Justice
Argus Health
Covington
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot